Telix partners with EDAP TMS and Profound Medical to integrate PSMA-PET imaging into image-guided prostate cancer ablation workflows.

ARS Pharmaceuticals reports $17.5M Q1 revenue; CVS Caremark formulary decision expected June will determine company's financial runway.

Accro Bioscience secures $50M Series C to advance AC-101, a RIPK2 inhibitor, into Phase IIb trials for ulcerative colitis...

Quince acquires Orphai and raises $187M to advance LAM-001, an inhaled rapamycin program, through Phase 2b trials across three...

Regeneron partners with Parabilis on antibody-helicon conjugates for $125M to target intracellular proteins resistant to existing drug modalities.

Hansa Biopharma licenses IDEFIRIX to SERB for €115M upfront, retaining U.S. rights while funding its FDA launch strategy through...

Teva's BBB- upgrade from Fitch on May 18 signals a new M&A-ready posture—and reveals a playbook other over-leveraged pharma...

A BIO China panel based on anonymous survey data from BD heads and senior dealmakers revealed that nearly 80%...

LOTTE Biologics expands its deal with Ottimo Pharma to include commercial process development for OTP-01, a biparatopic antibody in...

Cue Biopharma licenses anti-IgE antibody CUE-221 from Ascendast Health Sciences for food allergy development, with Phase 2b contingent on...